Please ensure Javascript is enabled for purposes of website accessibility

Should You Buy Inovio Pharmaceuticals Stock Right Now?

By Keith Speights - Feb 26, 2020 at 7:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is developing a potential vaccine for the coronavirus. Its pipeline is chock-full of other candidates. Time to buy?

Shares of Inovio Pharmaceuticals (INO -6.67%) skyrocketed in January with initial worries about the coronavirus outbreak in China. However, the stock gave up most of those gains over the next few weeks.

Now, though, concerns that the coronavirus could become a global pandemic are greater than ever. Inovio is one of a handful of drugmakers that are frantically scrambling to develop a vaccine for the deadly virus. Should you buy Inovio right now before the coronavirus threat potentially worsens? 

Gloved hand holding vial of blood with a label that has "coronavirus" printed on it with a check next to a box with a plus sign

Image source: Getty Images.

Understanding the landscape

Before answering whether you'd buy Inovio stock, it's first important to understand what's going on with coronavirus drug and vaccine development. Inovio announced on Jan. 23 that the Coalition for Epidemic Preparedness Innovations (CEPI) was giving it up to $9 million to advance Inovio's experimental vaccine INO-4800 through preclinical testing and phase 1 clinical studies in the U.S.

A week later, Inovio reported that it's partnering with Beijing Advaccine Biotechnology to develop INO-4800 in China. The two companies, along with the Wistar Institute and GeneOne Life Science subsidiary VGXI, plan to conduct a phase 1 clinical study evaluating the experimental vaccine in parallel with Inovio's testing of INO-4800 in the United States.

Although these updates were encouraging, the reality is that other drugmakers are farther along than Inovio is in developing potential coronavirus treatments and vaccines. Put Gilead Sciences at the top of that list. Bruce Aylward, assistant director-general of the World Health Organization, stated publicly this week that Gilead's remdesivir appears to be the one drug that WHO scientists think could be effective at treating the coronavirus.

Moderna is another leader in the race to fight the coronavirus. The biotech announced on Monday that its experimental vaccine mRNA-1273 is ready to begin testing in humans. Moderna has already shipped an initial batch of its vaccine to the National Institute of Allergy and Infectious Diseases (NIAID).

Inovio's other prospects

Inovio isn't only focused on the coronavirus, though. The biotech's lead pipeline candidate is VGX-3100. Inovio expects to report early data from its Reveal 1 phase 3 study evaluating the drug in treating cervical dysplasia in the fourth quarter of this year. 

The company also plans to report 12- and 18-month overall survival data this year for INO-5401 in treating glioblastoma. Inovio previously announced encouraging progression-free survival results after six months of treatment from its phase 2 study of INO-5401 and INO-9112 in combination with cancer immunotherapy Libtayo. The company's big partner, AstraZeneca, should also announce for MEDI-0457, which Inovio initially developed, in treating head and neck cancer this year.

Inovio recently received a green light from the U.S. Food and Drug Administration (FDA) to begin evaluating INO-3107 in a phase 1/2 clinical trial for treating recurrent respiratory papillomatosis (RRP). Like cervical dysplasia, RRP is caused by human papillomavirus (HPV) infections.

The biotech should also have milestones on the way for its other experimental vaccines. Inovio expects to present data later this year from its phase 1 study evaluating INO-4500 in preventing infection from the Lassa virus. It plans to report results in 2020 from its phase 1 study of INO-A002 in preventing or treating Zika virus infection. In addition, Inovio intends to advance experimental MERS vaccine INO-4700 to a phase 2 study in the Middle East and Africa.

To buy or not to buy?

Investing in biotech stocks can be a risky proposition. Investing in clinical-stage biotech stocks is even riskier.

Inovio certainly has plenty of pipeline candidates that could be successful down the road. However, there's no guarantee that any of them will pan out.

Also, Inovio's cash position stood at $93.8 million at the end of September 2019. That's not even enough to fund operations for a full year at the company's current rate of spending. It seems very likely that Inovio will have to raise additional capital, which could mean a dilution-causing stock offering.

The company isn't in the lead position in the race to develop a coronavirus vaccine. Its top candidate is still more than years away from possibly winning regulatory approval. I think that investors are better off holding off on buying Inovio stock right now. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.82 (-6.67%) $0.13
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$65.93 (-0.87%) $0.58
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.21 (-0.99%) $0.62
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$142.19 (-2.18%) $-3.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.